{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:28:02Z","timestamp":1794317282263,"version":"4.9.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-NHL) patients. However, a subset of patients who relapse after CD19CAR T-cell therapy have outgrowth of CD19\u2212 tumor cells. Hence, development of alternative CARs targeting other B-cell markers represents an unmet medical need for B-cell acute lymphoblastic leukemia and B-NHL. Here, we confirmed previous data by showing that, overall, B-NHL has high expression of CD37. A second-generation CD37CAR was designed, and its efficacy in T cells was compared with that of CD19CAR. In vitro assessment of cytotoxicity and T-cell function upon coculture of the CAR T cells with different target B-cell lymphoma cell lines demonstrated comparable efficacy between the 2 CARs. In an aggressive B-cell lymphoma xenograft model, CD37CAR T cells were as potent as CD19CAR T cells in controlling tumor growth. In a second xenograft model, using U2932 lymphoma cells containing a CD19\u2212 subpopulation, CD37CAR T cells efficiently controlled tumor growth and prolonged survival, whereas CD19CAR T cells had limited effect. We further show that, unlike CD19CAR, CD37CAR was not sensitive to antigen masking. Finally, CD37CAR reactivity was restricted to B-lineage cells. Collectively, our results demonstrated that CD37CAR T cells also can effectively eradicate B-cell lymphoma tumors when CD19 antigen expression is lost and support further clinical testing for patients with relapsed\/refractory B-NHL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018029678","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T16:55:20Z","timestamp":1555088120000},"page":"1230-1243","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1442","authenticated-orcid":false,"given":"Hakan","family":"K\u00f6ksal","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-9159","authenticated-orcid":false,"given":"Pierre","family":"Dillard","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Josefsson","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;"},{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solrun Melkorka","family":"Maggadottir","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Pollmann","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"F\u00e5ne","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvild Nuvin","family":"Blaker","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;"},{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Division of Cancer Medicine, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-670X","authenticated-orcid":false,"given":"Kanutte","family":"Huse","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;"},{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and"},{"name":"KG Jebsen Centre for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"additional","affiliation":[{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;"},{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0394-9986","authenticated-orcid":false,"given":"June H.","family":"Myklebust","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;"},{"name":"KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-3536","authenticated-orcid":false,"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5869-1746","authenticated-orcid":false,"given":"S\u00e9bastien","family":"W\u00e4lchli","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"4","key":"2020021109195699300_B1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"28","key":"2020021109195699300_B2","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021109195699300_B3","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2020021109195699300_B4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2020021109195699300_B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"224","key":"2020021109195699300_B6","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9967","key":"2020021109195699300_B7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"2020021109195699300_B8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2020021109195699300_B9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020021109195699300_B10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"355","key":"2020021109195699300_B11","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"2020021109195699300_B12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"24","key":"2020021109195699300_B13","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020021109195699300_B14","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2020021109195699300_B15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2020021109195699300_B16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"issue":"10","key":"2020021109195699300_B17","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2020021109195699300_B18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2020021109195699300_B19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2020021109195699300_B20","doi-asserted-by":"crossref","first-page":"e1000338","DOI":"10.1371\/journal.ppat.1000338","article-title":"The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity","volume":"5","author":"van Spriel","year":"2009","journal-title":"PLoS Pathog"},{"issue":"2","key":"2020021109195699300_B21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00418-015-1326-2","article-title":"Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs","volume":"144","author":"de Winde","year":"2015","journal-title":"Histochem Cell Biol"},{"issue":"5","key":"2020021109195699300_B22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2020021109195699300_B23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1172\/JCI81041","article-title":"Tetraspanin CD37 protects against the development of B cell lymphoma","volume":"126","author":"de Winde","year":"2016","journal-title":"J Clin Invest"},{"issue":"26","key":"2020021109195699300_B24","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020021109195699300_B25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.trecan.2017.04.006","article-title":"Novel insights into membrane targeting of B cell lymphoma","volume":"3","author":"de Winde","year":"2017","journal-title":"Trends Cancer"},{"issue":"14","key":"2020021109195699300_B26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas [published correction appears in Blood. 2018;132(23):2527]","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2020021109195699300_B27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"2020021109195699300_B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-3083.1985.tb01422.x","article-title":"Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor","volume":"21","author":"Smeland","year":"1985","journal-title":"Scand J Immunol"},{"issue":"1","key":"2020021109195699300_B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1472-6750-10-81","article-title":"Improved Tet-responsive promoters with minimized background expression","volume":"10","author":"Loew","year":"2010","journal-title":"BMC Biotechnol"},{"issue":"11","key":"2020021109195699300_B30","doi-asserted-by":"crossref","first-page":"e27930","DOI":"10.1371\/journal.pone.0027930","article-title":"A practical approach to T-cell receptor cloning and expression","volume":"6","author":"W\u00e4lchli","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"2020021109195699300_B31","doi-asserted-by":"crossref","first-page":"e1302631","DOI":"10.1080\/2162402X.2017.1302631","article-title":"T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth","volume":"6","author":"Inderberg","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"2020021109195699300_B32","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/s41598-017-11126-y","article-title":"A TCR-based chimeric antigen receptor","volume":"7","author":"Walseng","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"2020021109195699300_B33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2020021109195699300_B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2020021109195699300_B35","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2020021109195699300_B36","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","author":"Roberts","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2020021109195699300_B37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-cd19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial [abstract]","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020021109195699300_B38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2020021109195699300_B39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"2020021109195699300_B40","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"26","key":"2020021109195699300_B41","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","article-title":"Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma","volume":"128","author":"Xu-Monette","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020021109195699300_B42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2012.358","article-title":"U-2932: two clones in one cell line, a tool for the study of clonal evolution","volume":"27","author":"Quentmeier","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2020021109195699300_B43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"28","key":"2020021109195699300_B44","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109195699300_B45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109195699300_B46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"2020021109195699300_B47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2020021109195699300_B48","first-page":"2769","article-title":"177 Lu-Lilotomab Satetraxetan, a novel CD37-targeted antibody-radionuclide conjugate in relapsed non-Hodgkin\u2019s lymphoma (NHL): updated results of an ongoing phase I\/II study (LYMRIT 37-01) [abstract]","volume":"130","author":"Kolstad","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020021109195699300_B49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2020021109195699300_B50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2020021109195699300_B51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/8\/1230\/1554873\/advances029678.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/8\/1230\/1554873\/advances029678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:56:01Z","timestamp":1581414961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/8\/1230\/260137\/Preclinical-development-of-CD37CAR-Tcell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018029678","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}